These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11358199)

  • 41. [Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Sunohara N
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):527-31. PubMed ID: 10434715
    [No Abstract]   [Full Text] [Related]  

  • 42. Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy.
    Suzuki K; Awata S; Nakagawa K; Takano T; Matsuoka H
    Mov Disord; 2006 Jan; 21(1):123-4. PubMed ID: 16250024
    [No Abstract]   [Full Text] [Related]  

  • 43. [Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS].
    Andreassen MD; Pedersen S
    Ugeskr Laeger; 2000 Mar; 162(10):1366-70. PubMed ID: 10745673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Malignant-like neuroleptic syndrome: a sign to call attention to].
    Segado Soriano A; García Castaño J; del Toro Cervera J; Muiño Miguez A
    An Med Interna; 1995 Sep; 12(9):466-7. PubMed ID: 8924562
    [No Abstract]   [Full Text] [Related]  

  • 45. Shared features of neuroleptic malignant syndrome and alcohol abuse complications.
    Krystal AD; McEvoy JP
    J Clin Psychiatry; 1990 Dec; 51(12):523. PubMed ID: 2258367
    [No Abstract]   [Full Text] [Related]  

  • 46. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
    Fiore S; Persichino L; Anticoli S; De Pandis MF
    Acta Biomed; 2014 Dec; 85(3):281-4. PubMed ID: 25567468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The neuroleptic malignant syndrome--a review.
    Gibb WR; Lees AJ
    Q J Med; 1985 Aug; 56(220):421-9. PubMed ID: 2864716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroleptic malignant-like syndrome causing thrombocytopaenia: a rare association.
    Sahu H; Manjunath MB; Ray A; Vikram NK
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome: a case report].
    Terlikowska M; Marzański M
    Psychiatr Pol; 1995; 29(3):343-8. PubMed ID: 7652087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroleptic malignant syndrome complicating levodopa withdrawal.
    Reutens DC; Harrison WB; Goldswain PR
    Med J Aust; 1991 Jul; 155(1):53-4. PubMed ID: 2067442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy.
    Salazar ML; Eiland LS
    Pediatr Emerg Care; 2008 Oct; 24(10):691-3. PubMed ID: 19240673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The neuroleptic malignant syndrome].
    Duarte J; García Viejo MA; García Miguel FJ; Sempere AP
    Med Clin (Barc); 1994 Oct; 103(14):558. PubMed ID: 7799673
    [No Abstract]   [Full Text] [Related]  

  • 55. [Malignant neuroleptic syndrome and malignant hyperthermia--a comparison].
    Spiess-Kiefer C; Hippius H
    Fortschr Neurol Psychiatr; 1986 May; 54(5):158-70. PubMed ID: 2426164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fever and rigidity.
    Howard ZD; Rempell JS; Nadel ES; Brown DF
    J Emerg Med; 2011 Jun; 40(6):668-70. PubMed ID: 21074960
    [No Abstract]   [Full Text] [Related]  

  • 57. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal.
    Eiden C; Capdevielle D; Deddouche C; Boulenger JP; Blayac JP; Peyrière H
    J Addict Med; 2011 Dec; 5(4):302-3. PubMed ID: 21817917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroleptic malignant syndrome: a report of a case and review of the literature.
    Kanchanapongkul J
    J Med Assoc Thai; 1991 Oct; 74(10):481-4. PubMed ID: 1686780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Postoperative hyperthermic syndrome following antiparkinsonian drugs withdrawal: the pitfall of enteral refeeding.
    Casier I; Jeanjean A; Hantson P
    Anaesth Intensive Care; 2013 Nov; 41(6):814-5. PubMed ID: 24180734
    [No Abstract]   [Full Text] [Related]  

  • 60. Neuroleptic malignant syndrome.
    Paul GE; Landers DF; Newman T
    Nebr Med J; 1990 Mar; 75(3):46-9; discussion 49-50. PubMed ID: 2179748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.